ReWalk机器人技术 RWLK 深 沪
等待开盘 04-02 09:30:00 美东时间
1.0501
0.000
0.00%
华盛通- 最 高--
- 今 开--
- 成交量 0股
- 最 低 --
- 昨 收 1.0501
- 总市值 6293.98万
- 52周最高 109.20
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 47.0736
- 委 比 0.00%
- 总股本 5993.70万
- 历史最高 91782.60
- 量 比 0
- 振 幅 0.00%
- 历史最低 34.44
- 每 手 1
- 风险率 0.00%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Lifeward Successfully Closes on Strategic Partnership with Oramed
Lifeward Ltd. announced the closure of its strategic partnership with Oramed Pharmaceuticals Inc., acquiring Oramed's POD™ technology and securing up to $47 million in capital, with $10 million accessed. The partnership aims to diversify Lifeward's biomedical portfolio and enhance profitability, supporting its mission to innovate for individuals with physical limitations.
03-25 20:10
Lifeward Regains Compliance with Nasdaq Minimum Bid Price Requirement
Lifeward Ltd. has regained compliance with Nasdaq's minimum bid price requirement, maintaining a closing bid of $1.00 or higher for 10 consecutive days, ensuring continued listing on the Nasdaq Capital Market. The company, a leader in medical technology, focuses on innovative solutions for physical rehabilitation and recovery, including the ReWalk Exoskeleton and AlterG Anti-Gravity System.
03-11 12:00
Lifeward to Report Fourth Quarter and Full Year 2025 Financial Results on March 18, 2026
Lifeward Ltd. (Nasdaq: LFWD) announced it will release its fourth quarter and full year 2025 financial results before the markets open on March 18, 2026. CEO Mark Grant and CFO Almog Adar will host a conference call and live webcast at 8:30 a.m. EST. Access details are provided via toll-free and international phone numbers and a webcast link on the Company’s website. Lifeward designs innovative medical technologies to improve lives of individuals...
03-10 20:15
Lifeward Partners With Shirley Ryan AbilityLab to Expand ReWalk Exoskeleton Access
Lifeward Partners With Shirley Ryan AbilityLab to Expand ReWalk Exoskeleton Access Lifeward Ltd. is collaborating with Shirley Ryan AbilityLab to expand access to the ReWalk Personal Exoskeleton for people living with spinal cord injury. The joint effort will launch dedicated clinic days in the seco
03-02 21:03
Lifeward Announces Collaboration With Shirley Ryan AbilityLab to Expand Access for the ReWalk Personal Exoskeleton
Lifeward Ltd. and Shirley Ryan AbilityLab announce a collaboration to establish specialized clinic days at the latter's Chicago campus starting in Q2 2026. The clinics aim to accelerate evaluation and accessibility of the ReWalk Personal Exoskeleton for individuals with spinal cord injuries (SCI). This partnership will streamline the pathway from evaluation to real-world use of the exoskeleton, enhancing functional ambulation and independence. Sh...
03-02 13:00
Lifeward Announces Reverse Share Split
Mass., and Israel, Feb. 20, 2026 — Lifeward Ltd. (Nasdaq: LFWD), a global leader in innovative medical technology, announced it will complete a 1-for-12 reverse split of its ordinary shares effective February 24, 2026. The reverse split aims to meet Nasdaq’s continued listing standards by increasing the per-share price above the $1.00 threshold. As a result, the Company’s outstanding shares will decrease from approximately 18.3 million to 1.5 mil...
02-20 13:00
Lifeward’s ReWalk™ Personal Exoskeleton Now Covered by Aetna, Coverage Expands to Include Three of the Largest Medicare Advantage Insurers
Aetna has joined Humana and UnitedHealthcare in providing Medicare Advantage coverage for the ReWalk Personal Exoskeleton, a device approved for individuals with spinal cord injuries. Together, these three insurers cover approximately 16 million beneficiaries nationwide. The ReWalk system, FDA-approved, enables functional walking and has shown benefits in musculoskeletal and cardiopulmonary health. A beneficiary with a thoracic spinal cord injury...
02-17 13:00
UPDATE: Lifeward To Acquire Oramed's POD Technology And Secure Up To $47M Strategic Investment As Oramed Takes Up To 49.99% Stake
Transaction Will Transfer Oramed's Oral Drug Delivery Platform (POD™ Technology) to Lifeward and Positions Oramed as a Significant Shareholder
01-13 21:18
Oramed and Lifeward Announce Strategic Transaction
Transaction Will Transfer Oramed's Oral Drug Delivery Platform (POD™ Technology) to Lifeward and Positions Oramed as a Significant Shareholder Oramed will transfer POD™ platform to Lifeward ...
01-13 20:58
Lifeward Enters Transformative Strategic Investment and Partnership Agreement with Oramed to Create a Diversified Biomedical Innovation Company
Lifeward Ltd has secured up to $47 million in strategic investment from Oramed Pharmaceuticals and another investor to drive profitability and diversify its portfolio into biotech. Lifeward acquired Oramed's Protein Oral Delivery (POD™) technology, targeting the $600+ billion injectable drugs market, including the potential first oral insulin medicine, ORMD-0801. The transaction allows Lifeward to focus on existing MedTech products like ReWalk an...
01-13 13:00
